Education
About Us
Working with TipRanks
Follow Us
Elanco Animal Health (ELAN)
NYSE:ELAN
ELAN Stock Chart & Stats
$24.83
-$0.30(-2.54%)
At close: 4:00 PM EST
$24.83
-$0.30(-2.54%)
Day’s Range― - ―
52-Week Range$8.02 - $25.63
Previous CloseN/A
Volume2.53M
Average Volume (3M)4.28M
Market Cap
$12.34B
Enterprise Value$16.30B
Total Cash (Recent Filing)$505.00M
Total Debt (Recent Filing)$4.02B
Price to Earnings (P/E)340.6
Beta1.35
Next Earnings
Feb 24, 2026EPS Estimate
0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.19
Shares Outstanding496,863,460
10 Day Avg. Volume3,909,989
30 Day Avg. Volume4,280,125
Financial Highlights & Ratios
PEG Ratio-0.14
Price to Book (P/B)0.98
Price to Sales (P/S)1.35
P/FCF Ratio15.18
Enterprise Value/Market Cap1.32
Enterprise Value/Revenue3.55
Enterprise Value/Gross Profit7.66
Enterprise Value/Ebitda18.30
Forecast
1Y Price Target
$27.00Price Target Upside8.74% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Balance Sheet And Cash GenerationCompany's plan to generate at least $1 billion in free cash flow across 2026–2028 and reduce net leverage toward below 3x by 2027 would strengthen the balance sheet and enable strategic flexibility.
Innovation PipelineElanco's broad innovation pipeline, comprising more than 15 development projects and multiple potential blockbuster candidates, supports expectations for meaningful product-driven revenue growth if regulatory approvals and launches progress as planned.
Margin Expansion And Cost SavingsManagement's restructuring and US R&D and manufacturing investments target significant EBITDA margin expansion, with expected cost savings of roughly $25 million in 2026 and larger savings in 2027 to support profitability improvement.
Bears Say
Commercialization DependenceAchievement of revenue and margin goals depends heavily on successful commercialization and market uptake of multiple new products, creating downside risk if adoption lags expectations.
Earnings Growth ShortfallProjected EPS growth that is slightly below consensus could weigh on valuation and investor sentiment despite longer-term improvement expectations.
Regulatory And Launch Execution RiskSustained execution on regulatory milestones and global product launches is critical; delays or setbacks in approvals or rollouts would undermine medium-term targets.
Elanco Animal Health News
ELAN FAQ
What was Elanco Animal Health’s price range in the past 12 months?
Elanco Animal Health lowest stock price was $8.02 and its highest was $25.63 in the past 12 months.
What is Elanco Animal Health’s market cap?
Elanco Animal Health’s market cap is $12.34B.
When is Elanco Animal Health’s upcoming earnings report date?
Elanco Animal Health’s upcoming earnings report date is Feb 24, 2026 which is in 11 days.
How were Elanco Animal Health’s earnings last quarter?
Elanco Animal Health released its earnings results on Nov 05, 2025. The company reported $0.19 earnings per share for the quarter, beating the consensus estimate of $0.13 by $0.06.
Is Elanco Animal Health overvalued?
According to Wall Street analysts Elanco Animal Health’s price is currently Undervalued.
Does Elanco Animal Health pay dividends?
Elanco Animal Health does not currently pay dividends.
What is Elanco Animal Health’s EPS estimate?
Elanco Animal Health’s EPS estimate is 0.11.
How many shares outstanding does Elanco Animal Health have?
Elanco Animal Health has 496,863,460 shares outstanding.
What happened to Elanco Animal Health’s price movement after its last earnings report?
Elanco Animal Health reported an EPS of $0.19 in its last earnings report, beating expectations of $0.13. Following the earnings report the stock price went down -4%.
Which hedge fund is a major shareholder of Elanco Animal Health?
Currently, no hedge funds are holding shares in ELAN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Elanco Animal Health Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$27.00 (8.74% Upside)
$27.00 (8.74% Upside)
Blogger Sentiment
Bullish
ELAN Sentiment 75%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 3.5M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $841.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 0.7%
Last 30 Days ▲ 0.4%
Last 30 Days ▲ 0.4%
Technicals
SMA
Positive
20 days / 200 days
Momentum
115.53%
12-Months-Change
Fundamentals
Return on Equity
0.54%
Trailing 12-Months
Asset Growth
2.02%
Trailing 12-Months
Company Description
Elanco Animal Health
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.
ELAN Company Deck
ELAN Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
Elanco reported strong financial results for Q3 2025 with significant revenue growth from both farm and pet health segments. The company achieved notable success with innovation products, particularly Credelio Quattro. However, challenges in pricing growth and tempered Bovaer adoption were noted. Overall, the sentiment is positive, driven by strong performance and strategic achievements.View all ELAN earnings summariesELAN Stock 12 Month Forecast
Average Price Target
$27.00
▲(8.74% Upside)
Technical Analysis
Dr Reddy's Laboratories
―
Viatris
―
Teva Pharmaceutical
―
Zoetis
―
Phibro Animal Health
―
Ownership Overview
Currently, No data available
---